NCT06127836
Study of Near-Infrared Imaging With Indocyanine Green for Detection of Sentinel Lymph Nodes in People With Vulvar Cancer
StatusActive, Not Recruiting
PhaseNot applicable
Primary completion (estimated)
At risk: Primary completion moved at least 11 months later.
See at-risk trials from Memorial Sloan Kettering Cancer Center
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 4 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion pushed from Nov 2026 to Nov 2027
- Eligibility criteria expanded, about 8 words
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 40 to confirmed 22
- Site details revised at 8 of 8 sites
- Minor Study sites: 7 to 8v3
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
success of identifying the SLN
Timeframe: 18 months
Arms and interventions
patients undergoing preoperative lymphoscintigraphyExperimental
Patients will undergo radiocolloid lymphoscintigraphy before their surgery; the surgeon will be blinded to the results of this procedure. The surgeon will subsequently inject ICG in accordance with the SLN protocol in the operating room and will identify and remove the SLN by use of near-infrared imaging guidance only.
Procedures: ICG guided sentinel lymph node biopsy
Sites
8 sites in 1 country